Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-4
Closed -$261 1004
2025
Q2
$261 Hold
4
﹤0.01% 713
2025
Q1
$248 Hold
4
﹤0.01% 686
2024
Q4
$289 Sell
4
-114
-97% -$8.91K ﹤0.01% 613
2024
Q3
$9.61K Sell
118
-46
-28% -$3.68K ﹤0.01% 501
2024
Q2
$12.2K Buy
164
+49
+43% +$3.67K ﹤0.01% 649
2024
Q1
$8.97K Buy
+115
New +$8.55K ﹤0.01% 635
2022
Q4
Sell
-66
Closed -$4K 1130
2022
Q3
$4K Buy
66
+3
+5% +$208 ﹤0.01% 894
2022
Q2
$4K Buy
+63
New +$4.68K ﹤0.01% 816
2019
Q3
Sell
-48
Closed -$2K 259
2019
Q2
$2K Buy
+48
New +$2.22K ﹤0.01% 264

Other funds holding HOLX

Crewe Advisors's HOLX Position: Q3 2025 in Review

Crewe Advisors sold out of Hologic (HOLX) in Q3 2025, closing a stake of 4 shares — an estimated $261 sold.

Crewe Advisors first reported a position in HOLX in Q2 2019 and held it in 9 quarters. The position peaked at $12.2K in Q2 2024. 740 funds tracked by Wall St. Rank hold HOLX as of Q3 2025.

  • Crewe Advisors reported no remaining Hologic position as of Q3 2025 after selling out during the quarter.
  • Crewe Advisors sold 4 Hologic shares in Q3 2025, an estimated $261.
  • Crewe Advisors first reported a position in Hologic in Q2 2019 and held it in 9 quarters.
  • Crewe Advisors's Hologic position peaked at $12.2K in Q2 2024.
  • 740 funds tracked by Wall St. Rank held Hologic as of Q3 2025.

Based on Crewe Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.